Author

Charlie W. Lees

JAK Inhibition in Practice: Continuing the Story Thread (Pfizer INC)
JAK Inhibition in Practice: Continuing the Story Thread (Pfizer INC)

Charlie W. Lees  et al.

Webinar: COVID-19 & Digestive Health #6 | IBD: Treatment, Service and Research (Update)
Webinar: COVID-19 & Digestive Health #6 | IBD: Treatment, Service and Research (Update)

Charlie W. Lees  et al.

Webinar: COVID-19 & Digestive Health #3 | IBD: Treatment, Service and Research
Webinar: COVID-19 & Digestive Health #3 | IBD: Treatment, Service and Research

Charlie W. Lees  et al.

Can Flexible Treatment Administration Impact Outcomes in Inflammatory Bowel Disease? (Takeda Pharmaceuticals International AG)
Can Flexible Treatment Administration Impact Outcomes in Inflammatory Bowel Disease? (Takeda Pharmaceuticals International AG)

Charlie W. Lees  et al.

HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY

Charlie W. Lees  et al.

It takes two to tango in UC: let’s get in sync with our patients (Pfizer Inc.) (Complete Session)
It takes two to tango in UC: let’s get in sync with our patients (Pfizer Inc.) (Complete Session)

Charlie W. Lees  et al.

INFLAMMATORY BOWEL DISEASE: A PHENOME-WIDE PRE- AND POST-DIAGNOSTIC ASSOCIATION STUDY
INFLAMMATORY BOWEL DISEASE: A PHENOME-WIDE PRE- AND POST-DIAGNOSTIC ASSOCIATION STUDY

Charlie W. Lees  et al.

A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Charlie W. Lees  et al.

LATENT CROHN’S DISEASE SUBGROUPS ARE IDENTIFIED BY FAECAL CALPROTECTIN PROFILES: A RETROSPECTIVE ANALYSIS OF THE LOTHIAN CROHN’S DISEASE INCEPTION COHORT
LATENT CROHN’S DISEASE SUBGROUPS ARE IDENTIFIED BY FAECAL CALPROTECTIN PROFILES: A RETROSPECTIVE ANALYSIS OF THE LOTHIAN CROHN’S DISEASE INCEPTION COHORT

Charlie W. Lees  et al.

THE OUTCOMES OF PATIENTS TREATED WITH 2ND AND 3RD LINE BIOLOGICAL IN PERIANAL CROHN’S DISEASE (PCD) – A MULTICENTRE PROPENSITY SCORE MATCHED STUDY
THE OUTCOMES OF PATIENTS TREATED WITH 2ND AND 3RD LINE BIOLOGICAL IN PERIANAL CROHN’S DISEASE (PCD) – A MULTICENTRE PROPENSITY SCORE MATCHED STUDY

Charlie W. Lees  et al.

MULTIPLE INFLIXIMAB BIOSIMILAR SWITCHES APPEAR TO BE SAFE AND EFFECTIVE IN A REAL-WORLD IBD COHORT
MULTIPLE INFLIXIMAB BIOSIMILAR SWITCHES APPEAR TO BE SAFE AND EFFECTIVE IN A REAL-WORLD IBD COHORT

Charlie W. Lees  et al.

LONG-TERM VEDOLIZUMAB PERSISTENCE IN ULCERATIVE COLITIS: THE EDINBURGH IBD UNIT EXPERIENCE 2014-2022
LONG-TERM VEDOLIZUMAB PERSISTENCE IN ULCERATIVE COLITIS: THE EDINBURGH IBD UNIT EXPERIENCE 2014-2022

Charlie W. Lees  et al.

BOTH SINGLE AND MULTIPLE SWITCHING BETWEEN INFLIXIMAB BIOSIMILARS CAN BE SAFE AND EFFECTIVE IN IBD: REAL WORLD OUTCOMES FROM THE EDINBURGH IBD UNIT
BOTH SINGLE AND MULTIPLE SWITCHING BETWEEN INFLIXIMAB BIOSIMILARS CAN BE SAFE AND EFFECTIVE IN IBD: REAL WORLD OUTCOMES FROM THE EDINBURGH IBD UNIT

Charlie W. Lees  et al.

FACTORS INDEPENDENTLY ASSOCIATED WITH FATIGUE IN IBD: RESULTS FROM THE BASELINE DATASET OF THE PREDICCT STUDY
FACTORS INDEPENDENTLY ASSOCIATED WITH FATIGUE IN IBD: RESULTS FROM THE BASELINE DATASET OF THE PREDICCT STUDY

Charlie W. Lees  et al.

PATIENT PERCEPTIONS ABOUT CAUSES OF FLARE IN INFLAMMATORY BOWEL DISEASE (IBD): RESULTS FROM THE BASELINE DATASET OF THE PREDICCT STUDY
PATIENT PERCEPTIONS ABOUT CAUSES OF FLARE IN INFLAMMATORY BOWEL DISEASE (IBD): RESULTS FROM THE BASELINE DATASET OF THE PREDICCT STUDY

Charlie W. Lees  et al.

PREDICCT COHORT BASELINE HABITUAL NUTRIENT INTAKE BY IBD PATIENTS
PREDICCT COHORT BASELINE HABITUAL NUTRIENT INTAKE BY IBD PATIENTS

Charlie W. Lees  et al.

LONG-TERM OUTCOMES FOLLOWING A SWITCH FROM ORIGINATOR ADALIMUMAB TO THE BIOSIMILAR SB5 (IMRALDI) IN IBD
LONG-TERM OUTCOMES FOLLOWING A SWITCH FROM ORIGINATOR ADALIMUMAB TO THE BIOSIMILAR SB5 (IMRALDI) IN IBD

Charlie W. Lees  et al.

COVID-19 VACCINE-INDUCED ANTIBODY AND T CELL RESPONSES IN IMMUNOSUPPRESSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER THE THIRD VACCINE DOSE
COVID-19 VACCINE-INDUCED ANTIBODY AND T CELL RESPONSES IN IMMUNOSUPPRESSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER THE THIRD VACCINE DOSE

Charlie W. Lees  et al.

Item 1 - 18 / 18
1